AGAnthony A. Gaspari

Anthony A. Gaspari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony A. Gaspari has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2017
      • Vol. 15  (6) , 471-472

    Immunologic Studies of Progesterone-Induced Neutrophilic Urticaria.

    by Papapit Tuchinda, Corinne Erickson, Antonella Tammaro, Miya Okada Paterniti, Sarbjit S Saini, Anthony A Gaspari

    A 33-year-old woman presented with recurring pruritic, erythematous papules around the mouth and on the hands, of 1.5 years' duration. These flares typically began several days before her menstrual cycle and persisted for approximately 1 week. Physical examination revealed urticarial plaques on the neck. Due to the nature of the eruption, which corresponded with her menstrual cycle, a diagnosis of autoimmune progesterone urticaria was considered and workup pursued.

  • Toll-Like Receptors

    by Jessica Shiu, Anthony A. Gaspari


  • Open Access

    New and emerging biologic therapies for moderate‐to‐severe plaque psoriasis: mechanistic rationales and recent clinical data forIL‐17 andIL‐23 inhibitors

    by Anthony A. Gaspari, Stephen Tyring

    The development of effective and well‐tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate‐to‐severe psoriasis include three tumor necrosis factor alpha inhibitors and an interleukin‐12/interleukin‐23 inhibitor. The establishment of the immunological basis of psoriasis has led to the development of biologic agents targeting specific downstream mediators in the psoriatic cascade. These drugs inhibit cytokines and cytokine signaling/transcription mediators like interleukin‐17, which plays an important role in immunopathogenesis. Several interleukin‐17 inhibitors are undergoing phase 3 clinical studies. In addition, biologics that selectively inhibit interleukin‐23 have been assessed in phase 2 studies. This review describes how the dissection of pathways in the immunopathogenesis of psoriasis has led to the development of therapeutic agents and highlights the latest clinical efficacy, safety and tolerability data on new and emerging biologic therapies that selectively target interleukin‐17 or interleukin‐23.


  • Significance of Dermatologic Findings in a Cohort of Depleted Uranium–Exposed Veterans of Iraqi Conflicts

    by Jessica Shiu, Joanna Gaitens, Katherine S. Squibb, Patricia W. Gucer, Melissa A. McDiarmid, Anthony A. Gaspari

    Background: Depleted uranium (DU)–containing weapons have been used in military operations since 1991. There is interest in following veterans who were occupationally exposed to DU by either inhalation or retention of fragments. A cohort of DU-exposed Gulf War I veterans has been followed longitudinally at the Baltimore Veterans Administration Medical Center since 1993. Objective: The aim was to monitor chronic dermatological findings associated with occupational DU exposure in the 2013 cohort. Methods: Thirty-five veterans were evaluated. This study was reviewed and approved by the institutional review board and the Baltimore Veterans Administration Medical Center research service. Depleted uranium exposure was measured using creatinine-adjusted urine uranium concentrations (micrograms of uranium per gram of creatinine [μgU/gCrea]). Detailed medical histories, physical examinations, and exposure histories were performed. Results: Using a cutoff level of 0.1 μgU/gCrea, 11 veterans were placed in the high-uranium exposure group, whereas 23 veterans were placed in the low-uranium exposure group. Retained fragments were documented in 91% of the high-exposure group versus that in 13% of the low-exposure group ( P < 0.001), and fragment-related scarring was significantly increased in the high-exposure group ( P = 0.002). Other dermatological findings such as dermatitis were also assessed. Conclusions: Fragment retainment and related scarring was significantly increased in veterans exposed to high levels of DU. Continuous monitoring of this cohort will yield interesting dermatological findings related to DU exposure.


  • Ultraviolet Radiation Signaling through TLR4/MyD88 Constrains DNA Repair and Plays a Role in Cutaneous Immunosuppression

    by Erin Harberts, Hua Zhou, Rita Fishelevich, Juan Liu, Anthony A Gaspari

    UV radiation (UVR) induces DNA damage, leading to the accumulation of mutations in epidermal keratinocytes and immunosuppression, which contribute to the development of nonmelanoma skin cancer. We reported previously that the TLR4–MyD88 signaling axis is necessary for UV-induced apoptosis. In the dinitrofluorobenzene contact hypersensitivity model, UV-irradiated MyD88-deficient (MyD88−/−) C57BL/6 mice had intact ear swelling, exaggerated inflammation, and higher levels of dinitrofluorobenzene-specific IgG2a compared with wild-type (WT) mice. Even with normal UV-induced, dendritic cell migration, DNA damage in the local lymph nodes was less pronounced in MyD88−/− mice compared with WT mice. Cultured, UV-irradiated WT APCs showed cleavage (inactivation) of the DNA damage–recognition molecule PARP, whereas PARP persisted in MyD88−/− and TLR4−/− APCs. Epidermal DNA from in vivo UV-irradiated MyD88−/− mice had an increased resolution rate of cyclobutane pyrimidine dimers. Both in vitro treatment of MyD88−/− APCs with and intradermal in vivo injections of PARP inhibitor, PJ-34, caused WT-level cyclobutane pyrimidine dimer repair. Lymphoblasts deficient in DNA repair (derived from a xeroderma pigmentosum group A patient) failed to augment DNA repair after MyD88 knockdown after UVR, in contrast to lymphoblasts from a healthy control. These data suggest that interference with the TLR4/MyD88 pathway may be a useful tool in promoting DNA repair and maintaining immune responses following UVR-induced damage.


  • IL-9 Regulates Allergen-Specific Th1 Responses in Allergic Contact Dermatitis

    by Juan Liu, Erin Harberts, Antonella Tammaro, Nicholas Girardi, Renata B. Filler, Rita Fishelevich, Angela Temann, Paula Licona-Limón, Michael Girardi, Richard A. Flavell, et al.


  • Human in vitro skin organ culture as a model system for evaluating DNA repair

    by Hannah Liu, Papapit Tuchinda, Rita Fishelevich, Erin Harberts, Anthony A. Gaspari


  • Manganese Oxidation State as a Cause of Irritant Patch Test Reactions

    by Laurie Shallcross, Simon Ritchie, Erin Ba Harberts, Antonella Tammaro, Joanna Gaitens, Anthony A. Gaspari

    Background: Manganese chloride (MnCl 2 ) 2.5% is included in the extended metals patch test series to evaluate patients for contact hypersensitivity to this metal salt. Objectives: The objective of this study was to prospectively determine the rate of allergic and irritant patch test reactions to MnCl 2 (Mn(II)), Mn 2 O 3 (Mn(III)), and KMnO 4 (Mn(VII)) in a cohort of patients undergoing patch testing. Methods: Fifty-eight patients were patch tested with MnCl 2 , Mn 2 O 3 , and KMnO 4 , each at 2.5% in petrolatum. Patch readings were taken at 48, and 72 or 96 hours, and scored using standard methods. Cultured monolayers of keratinocytes (KCs) were exposed to MnCl 2 , Mn 2 O 3 , and KMnO 4 in aqueous culture medium, and cell survival and cytokine release were studied. Conclusions: MnCl 2 caused irritant patch test reactions in 41% of the cohort, whereas Mn 2 O 3 and KMnO 4 caused a significantly lower rate of irritant reactions (both 3%). No allergic morphologies were observed. Similarly, in cultured KC monolayers, only MnCl 2 was cytotoxic to KC and induced tumor necrosis factor α release. The oxidation state of manganese used for patch testing affects the irritancy of this metal salt, as Mn(II) caused an unacceptably high rate of irritant reactions in a cohort of patients. In vitro studies confirmed these clinical data, as only Mn(II) was cytotoxic to cultured monolayers of KC.


  • Open Access

    MyD88 mediates the decision to die by apoptosis or necroptosis after UV irradiation

    by Erin Harberts, Rita Fishelevich, Juan Liu, Sergei P Atamas, Anthony A Gaspari

    UV irradiation-induced cellular damage is classically associated with apoptosis and is known to result in systemic immunosuppression. How the decision to undergo apoptosis is made following UV is not fully understood. We hypothesize that a central mediator of TLR signaling, MyD88, determines cell fate after UV exposure. Survival after UV of immortalized bone marrow-derived macrophages (BMDM) and ex vivo peritoneal macrophages (PM) from MyD88 germline-deficient mice (MyD88-/-) was significantly higher than wild type (WT) PM. UV-induced apoptosis (DNA laddering) in PM and epidermis of MyD88-/- animals versus WT was decreased. In MyD88-/- PM, decreased cleavage of caspase 3, as well as pro-necroptotic protein, RIP1, and a significant increase in transcription and release of pro-inflammatory TNF-α, suggest that necroptosis, rather than apoptosis, has been initiated. In vivo studies confirm this hypothesis after UV, showing low apoptosis by TUNEL and inflammation in MyD88-/- skin sections. Considering that MyD88 participates in many TLR pathways, BMDM from TLR2-/-, TLR4-/- and WT mice were compared for evidence of UV-induced apoptosis. Only TLR4-/- BMDM and PM had a similar phenotype to MyD88-/-, suggesting that the TLR4–MyD88 axis importantly contributes to cell fate decision. Our study describes a new cellular consequence of MyD88 signaling after UV, and may provide rationale for therapies to mitigate UV-induced immunosuppression.


  • Merkel Cell Polyomavirus Detection in a Patient with Familial Epidermodysplasia Verruciformis

    by Eun‐Kyung M. Kwon, Christian R. Halvorson, Peter Rady, Stephen Tyring, Harrison P. Nguyen, Grace F. Kao, Anthony A. Gaspari

    We report a case of Merkel cell polyomavirus detection in the skin of a patient with epidermodysplasia verruciformis (EDV) and a family history remarkable for an unusual inheritance pattern for EDV.